Literature DB >> 30814055

Pharmacologic control of CAR-T cell function using dasatinib.

Evan W Weber1, Rachel C Lynn1, Elena Sotillo1, John Lattin1, Peng Xu1, Crystal L Mackall1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 30814055      PMCID： PMC6418502          DOI： 10.1182/bloodadvances.2018028720

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  27 in total

1.  Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Authors:  Christopher A Pennell; Jessie L Barnum; Cameron S McDonald-Hyman; Angela Panoskaltsis-Mortari; Megan J Riddle; Zhengming Xiong; Michael Loschi; Govindarajan Thangavelu; Heather M Campbell; Meghan D Storlie; Yosef Refaeli; Scott N Furlan; Michael C Jensen; Leslie S Kean; Jeffrey S Miller; Jakub Tolar; Mark J Osborn; Bruce R Blazar
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

2.  Lck is a key target of imatinib and dasatinib in T-cell activation.

Authors:  K C Lee; I Ouwehand; A L Giannini; N S Thomas; N J Dibb; M J Bijlmakers
Journal:  Leukemia       Date:  2010-02-11       Impact factor: 11.528

3.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Authors:  Iulia Diaconu; Brandon Ballard; Ming Zhang; Yuhui Chen; John West; Gianpietro Dotti; Barbara Savoldo
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

4.  Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

Authors:  Nathan Singh; Ted J Hofmann; Zachary Gershenson; Bruce L Levine; Stephan A Grupp; David T Teachey; David M Barrett
Journal:  Cytotherapy       Date:  2017-05-11       Impact factor: 5.414

5.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

6.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

Review 7.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

8.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

9.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

10.  Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Authors:  George D Demetri; Patricia Lo Russo; Iain R J MacPherson; Ding Wang; Jeffrey A Morgan; Valerie G Brunton; Prashni Paliwal; Shruti Agrawal; Maurizio Voi; T R Jeffry Evans
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531
View more
  50 in total

1.  Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo.

Authors:  Sarah A Richman; Liang-Chuan Wang; Edmund K Moon; Uday R Khire; Steven M Albelda; Michael C Milone
Journal:  Mol Ther       Date:  2020-06-11       Impact factor: 11.454

Review 2.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

Review 3.  Cellular therapy: Immune-related complications.

Authors:  Joseph H Oved; David M Barrett; David T Teachey
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

Review 4.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

5.  BiTEs better than CAR T cells.

Authors:  Marion Subklewe
Journal:  Blood Adv       Date:  2021-01-26

Review 6.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

7.  A New Safety Approach Allowing Reversible Control of CAR T Cell Responses.

Authors:  Amanda X Y Chen; Imran G House; Paul A Beavis; Phillip K Darcy
Journal:  Mol Ther       Date:  2020-06-18       Impact factor: 11.454

Review 8.  Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.

Authors:  Cassie K Chou; Cameron J Turtle
Journal:  Expert Opin Biol Ther       Date:  2020-02-24       Impact factor: 4.388

9.  Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.

Authors:  Olli Dufva; Jan Koski; Pilvi Maliniemi; Aleksandr Ianevski; Jay Klievink; Judith Leitner; Petri Pölönen; Helena Hohtari; Khalid Saeed; Tiina Hannunen; Pekka Ellonen; Peter Steinberger; Matti Kankainen; Tero Aittokallio; Mikko A I Keränen; Matti Korhonen; Satu Mustjoki
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

Review 10.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.